Intranasal immunisation with conjugate vaccine protects mice from systemic and respiratory tract infection with Pseudomonas aeruginosa

Keyphrases

• Pseudomonas Aeruginosa (P. aeruginosa) 100%
• Conjugate Vaccine 100%
• Respiratory Infection 100%
• Intranasal Immunization 100%
• Intranasal Route 66%
• Lung Infection 33%
• Oligonucleotides 33%
• Immunization 33%
• Burn Sepsis 33%
• Opsonophagocytosis 33%
• Intratracheal 33%
• IgA Antibody 33%
• Serum IgG 33%
• Anti-Pseudomonas 33%
• Mucosal Immunity 33%
• Upper Respiratory Tract 33%
• Intranasal Application 33%
• Cholera Toxin 33%
• Systemic Immunity 33%
• Mucosal IgA 33%
• IgG Subclass Antibodies 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Mouse 100%
• Pseudomonas aeruginosa 100%
• Respiratory Tract Infection 100%
• Conjugate Vaccine 100%
• Adjuvant 66%
• Intranasal Route 66%
• Lung Infection 33%
• Wound Infection 33%
• Oligonucleotide 33%
• Burn 33%
• Immunoglobulin A Antibody 33%
• Respiratory Tract 33%
• Pseudomonas 33%
• Cholera Toxin 33%

Medicine and Dentistry

• Pseudomonas aeruginosa 100%
• Respiratory Tract Infection 100%
• Conjugate Vaccine 100%
• Adjuvant 66%
• Intranasal Route 66%
• In Vitro 33%
• Secretion (Process) 33%
• Lung Infection 33%
• Wound Infection 33%
• Thermal Burn 33%
• Immunoglobulin A Antibody 33%
• Oligonucleotide 33%
• Mucosal Immunity 33%
• Pseudomonas 33%
• Upper Respiratory Tract 33%
• Cholera Toxin 33%